Zhi Tong Cai Jing·2025-08-18 07:11Core Viewpoint - Junshi Biosciences (01877) has seen a significant stock increase of over 18%, currently trading at 36.4 HKD with a transaction volume of 809 million HKD, following the acceptance of new drug applications by the National Medical Products Administration for its PD-1 monoclonal antibody, Toripalimab, and an ADC drug, Vidutolimab, for new indications in cancer treatment [1][1]. Group 1 - Junshi Biosciences announced that the National Medical Products Administration has accepted its application for Toripalimab and Vidutolimab for new indications in treating locally advanced or metastatic urothelial carcinoma patients [1][1]. - This marks the thirteenth indication application for Toripalimab submitted in mainland China [1][1]. - Changjiang Securities views Junshi Biosciences as one of the earliest innovative biotech companies in China, with Toripalimab being the first PD-1 monoclonal antibody approved in the country [1][1]. Group 2 - The current timing indicates that Junshi Biosciences is experiencing accelerated sales in its existing business, with innovative assets set to enter Phase III clinical trials soon [1][1]. - Several significant assets are in need of value reassessment, and the company has a well-established early research platform and asset reserve [1][1]. - The fundamental turning point for the company is becoming evident [1][1].